Unlocking Treg therapeutics: cutting-edge preclinical models for CCR8-targeting agents in efficacy and safety assessment

Content

‍

▶️ Key differences in CCR8 biology between humans and mice, including expression patterns and ligand interactions, and their impact on translational research

‍

▶️ Efficacy assessment using the genO-hCCR8/hCCL1/hFcγR model to evaluate CCR8-targeting depleting agents

‍

▶️ Safety and pharmacodynamic evaluation with the genO-BRGSF-HIS model to support preclinical safety assessment

Speaker

‍

Fabiane Sônego, PhD in Immunology and Pharmacology, is the Director of Preclinical Models and Services at genOway. She has extensive expertise in in vivo models for immuno-oncology and inflammation and a proven track record of supporting researchers in advancing translational research and accelerating drug development.

‍